Aurobindo Pharma's Telangana Unit Gets 3 US FDA Observations

• Aurobindo Pharma's subsidiary Apitoria Pharma's Telangana Unit-V received 3 observations (Form 483) from the US FDA after a recent inspection.
• The company stated these observations are procedural and committed to responding to the US FDA within the stipulated timeframe.
• Aurobindo Pharma reported a 4% increase in Q2 profit to Rs 848 crore, with revenue from operations rising to Rs 8286 crore.
• The company's share price closed up 1.95% on Friday but has seen a 1.61% decline over the past year.

Why It Matters: US FDA objections to Aurobindo Pharma's unit signal potential operational and stock impact.